Abstract：
The chemotherapeutic drug of doxorubicin (DOX) has witnessed widespread applications for treating various cancers. DOX-treated dying cells bear cellular modifications which allow enhanced presentation of tumor antigen and neighboring dendritic cell activation. Furthermore, DOX also facilitate the immune-mediated clearance of tumor cells. However, disadvantages such as severe off-target toxicity, and prominent hydrophobicity have resulted in unsatisfactory clinical therapeutic outcomes. The effective delivery of DOX drug molecules is still challenging despite the rapid advances in nanotechnology and biomaterials. Huge progress has been witnessed in DOX nanoprodrugs owing to their brilliant benefits such as tumor stimuli-responsive drug release capacity, high drug loading efficiency and so on. This review summarized recent progresses of DOX prodrug-based nanomedicines to provide deep insights into future development and inspire researchers to explore DOX nanoprodrugs with real clinical applications.
摘要：
化疗药物多柔比星(DOX)已经见证了用于治疗各种癌症的广泛应用。DOX处理的垂死细胞具有细胞修饰，可增强肿瘤抗原的呈递和邻近的树突状细胞的活化。此外，DOX还促进免疫介导的肿瘤细胞清除。然而,缺点，如严重的脱靶毒性，和突出的疏水性导致不令人满意的临床治疗结果。尽管纳米技术和生物材料的快速发展，DOX药物分子的有效递送仍然具有挑战性。巨大的进步已经见证了DOX纳米前药由于其辉煌的好处，如肿瘤刺激响应的药物释放能力，具有载药效率高等特点。本文综述了基于DOX前药的纳米药物的最新进展，为未来的发展提供了深刻的见解，并激励研究人员探索具有实际临床应用的DOX纳米前药。
